Madrigal Pharmaceuticals (MDGL) Net Income Growth (3y) (2013 - 2026)

Madrigal Pharmaceuticals (MDGL) Net Income Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.16%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -3.84%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 79.26%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Madrigal Pharmaceuticals 16.03 Bn 15.80 Bn - -6.27%

Historic Data

Download Data
DateValue
Mar 31, 2026 -6.27%
Dec 31, 2025 -26.03%
Sep 30, 2025 -11.02%
Jun 30, 2025 15.79%
Mar 31, 2025 -8.39%
Dec 31, 2024 10.78%
Sep 30, 2024 -19.23%
Jun 30, 2024 -35.08%
Mar 31, 2024 -40.83%
Dec 31, 2023 16.33%
Sep 30, 2023 -19.42%
Jun 30, 2023 -20.43%
Mar 31, 2023 -28.57%
Dec 31, 2022 2.80%
Sep 30, 2022 -55.65%
Jun 30, 2022 -53.05%
Mar 31, 2022 -56.14%
Dec 31, 2021 -8.58%
Sep 30, 2021 -94.89%
Jun 30, 2021 -109.09%